Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-7. Canceled.
- 8. (Currently amended) A compound having the following general formula (VII)

wherein (VI) is the general formula: (VI) according to claim 6

wherein R_a is a phenyl group; a substituted phenyl group having one or more substituents wherein the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C₁₋₄alkylamino, C₁₋₄dialkylamino, halogen, perfluoro C₁₋₄alkyl, C₁₋₃alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups; a benzyl group; a substituted benzyl group with one or more substituents where the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C₁₋₄alkylamino, C₁₋₄dialkylamino, halogen, perfluoro C₁₋₄alkyl, C₁₋₃alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl group; or a bicyclic aryl group having 8 to 11 ring members, which may have 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur;

R_b is a monocyclic aryl group having 5 to 7 ring members, which may have 1 to 2 heteroatoms selected from nitrogen, oxygen or sulfur, and aryl ring in the compound

may have one or more substituents selected from a group consisting of halide, hydroxy, cyano, lower alkyl, and lower alkoxy groups;

Rc is a saturated or unsaturated $C_{1.6}$ alkyl, $C_{1.6}$ alkoxy, perfluoro $C_{1.6}$ alkyl group; and

 X_1 , X_2 , and X_3 may be the same or different and independently selected from hydrogen, hydroxyl, and halide;

Y is oxygen, sulfur, or nitrogen of a group selected from R_a , R_b , R_c , X_1 , X_2 and X_3 ; R_{10} is phosphate, hemisuccinate, phosphoryloxymethyloxycarbonyl, dimethylaminoacetate, amino acid, or a salt-htereof thereof; and

the compound having general formula (VII) is capable of serving as a substrate for a phosphatase or a carboxylase and is thereby converted to a compound having general formula (VI).

9-11. Canceled.

- 12. (Currently amended) A pharmaceutical composition comprising a compound according to any one of claims 1-8 and a pharmaceutically acceptable carrier.
- 13. (Currently amended) A<u>The</u> pharmaceutical composition of claim 12, the eomposition comprising a safe and effective amount of the compound.

14-15. Canceled.

- 16. (Currently amended) A method for carrying out a binding assay, comprising:
- a) providing a composition comprising a first co-activator and an interacting protein, said first co-activator comprising a binding motif of LXXLL, LXXLI or FXXFF wherein X is any amino acid;
- b) combining the first co-activator and the interacting protein with a test compound; and

- c) detecting alteration in binding between the first co-activator and the interacting protein in the presence of the compound; wherein the test compound is selected from a compound of any one of claims 1-8.
- 17. (Original) The method of claim 16, wherein said interacting protein is a transcription factor or a second co-activator.
- 18. (Original) The method of claim 16, wherein said interacting protein is selected from the group consisting of RIP140; SRC-1 (NCoA-1); TIF2 (GRIP-1; SRC-2); p (CIP; RAC3; ACTR; AIB-1; TRAM-1; SRC-3); CBP (p300); TRAPs (DRIPs); PGC-1; CARM-1; PRIP (ASC-2; AIB3; RAP250; NRC); GT-198; and SHARP (CoAA; p68; p72).
- 19. (Original) The method of claim 16, wherein said interacting protein is selected from the group consisting of TAL 1; p73; MDm2; TBP; HIF-1; Ets-1; RXR; p65; AP-1; Pit-1; HNF-4; Stat2; HPV E2; BRCA1; p45 (NF-E2); c-Jun; c-myb; Tax; Sap 1; YY1; SREBP; ATF-1; ATF-4; Cubitus; Interruptus; Gli3; MRF; AFT-2; JMY; dMad; PyLT: HPV E6; CITTA; Tat; SF-1; E2F; junB; RNA helicase A; C/EBP β; GATA-1; Neuro D; Microphthalimia; E1A; TFIIB; p53; P/CAF; Twist; Myo D; pp9O RSK; c-Fos; and SV40 Large T.
- 20. (Original) The method of claim 16, wherein said interacting protein is selected from the group consisting of ERAP140; RIP140; RIP160; Trip1; SWI1 (SNF); ARA70; RAP46; TIF1; TIF2; GRIP1; and TRAP.
- 21. (Original) The method of claim 16, wherein said interacting protein is selected from the group consisting of VP16; VP64; p300; CBP; PCAF; SRC1 PvALF; AtHD2A; ERF-2; OsGAI; HALF-1; C1; AP-1; ARF-5; ARF-6; ARF-7; ARF-8; CPRF1; CPRF4; MYC-RP/GP; and TRAB1.
- 22. (Original) The method of claim 16, wherein said first co-activator is CBP or p300.

- 23. (Currently amended) A method for inhibiting tumor growth comprising administering to a mammalian subject having a tumor a compound according to any one of claims 1-8, or a composition according to claim 12 or claim 13, in an amount effective to inhibit the growth of the tumor in the mammalian subject.
 - 24. (Original) The method of claim 23 wherein the tumor is cancerous.
- 25. (Original) The method of claim 23 wherein the tumor is colorectal cancer.
- 26. (Currently amended) A method of treating or preventing cancer comprising administering to a subject in need thereof a compound according to any one of claims 1-8, or a composition according to claim 12 or claim 13, in an amount effective to treat or prevent the cancer.
- 27. (Original) The method of claim 26 wherein the cancer is colorectal cancer.
- 28. (Original) The method of claim 26 wherein the compound or the composition is administered in combination with an anti-neoplastic agent.
- 29. (Original) The method of claim 28 wherein the anti-neoplastic agent is selected from the group consisting of 5-FU, taxol, cisplatin, mitomycin C, tegafur, raltitrexed, capecitabine, and irinotecan.
- 30. (Currently amended) A method of treating or preventing restenosis associated with angioplasty comprising administering to a subject in need thereof an amount of a compound according to any one of claims 1-8, or a composition according to claim 12 or claim 13, where the amount is effective to prevent the restenosis.

- 31. (Currently amended) A method of treating or preventing polycystic kidney disease comprising administering to a subject in need thereof an amount of a compound according to any one of claims 1-8, or a composition according to claims 12 or 13, where the amount is effective to treat the polycystic kidney disease.
- 32. (Currently amended) A method of treating or preventing aberrant angiogenesis disease comprising administering to a subject in need thereof an amount of a compound according to any one of claims 1-8, or a composition according to claim 12 or claim 13, where the amount is effective to treat the aberrant angiogenesis disease.
- 33. (Currently amended) A method of treating or preventing rheumatoid arthritis disease comprising administering to a subject in need thereof an amount of a compound according to any one of claims 1-8, or a composition according to claim 12 or claim 13, where the amount is effective to treat the rheumatoid arthritis disease.
- 34. (Currently amended) A method of treating or preventing ulcerative colitis comprising administering to a subject in need thereof an amount of a compound according to any one of claims 1-8, or a composition according to claim 12 or claim 13, where the amount is effective to treat the ulcerative colitis.
- 35. (Currently amended) A method for treating or preventing tuberous sclerosis complex (TSC) comprising administering to a subject in need thereof an amount of a compound of any of claims 1-8, or a composition of claim 12 or claim 13, where the amount is effective to treat or prevent TSC.
- 36. (Currently amended) A method for treating or preventing a KSHV-associated tumor comprising administering to a subject in need thereof an amount of a compound of any of claims 1-8, or a composition of claim 12 or claim 13, where the amount is effective to treat or prevent the KSHV-associated tumor.

- 37. (Currently amended) A method for modulating hair growth comprising administering to a subject in need thereof an amount of a compound of any of claims 1-8, or a composition of claim 12 or claim 13, where the amount is effective to modulate hair growth on the subject.
- 38. (Currently amended) A method of treating or preventing Alzheimer's disease comprising administering to a subject in need thereof an amount of a compound according to any one of claims 1-8, or a composition according to claim 12 or claim 13, where the amount is effective to treat or prevent Alzheimer's disease.
- 39. (Currently amended) A method for promoting neurite outgrowth, comprising contacting a neuron with a compound according to any one of claims 1-8, or a composition according to claim 12 or claim 13, in an amount effective to promote neurite outgrowth.
- 40. (Currently amended) A method for promoting differentiation of a neural stem cell comprising contacting a neural stem cell with a compound according to any one of claims 1-8, or a composition according to claim 12 or claim 13, where the amount is effective to promote differentiation of the neural stem cell.
- 41. (Currently amended) A method for promoting apoptosis in cancer cells comprising contacting cancer cells with a compound according to any one of claims 1-8, or a composition according to claim 12 or claim 13, in an amount effective to promote apoptosis in the cancer cells.
- 42. (Currently amended) A method for inhibiting survivin expression in a cell comprising contacting a survivin-expressing cell with a compound according to any one of claims 1-8, or a composition according to claim 12 or claim 13, in an amount effective to inhibit survivin expression.

43. (New) The compound of claim 8, wherein

 R_a is a phenyl group; a substituted phenyl group having one or more substituents wherein the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, $C_{1.4}$ alkylamino, $C_{1.4}$ dialkylamino, halogen, perfluoro $C_{1.4}$ alkyl, $C_{1.4}$ alkyl, $C_{1.3}$ alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups; a benzyl group; a substituted benzyl group with one or more substituents where the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, $C_{1.4}$ alkylamino, $C_{1.4}$ dialkylamino, halogen, perfluoro $C_{1.4}$ alkyl, $C_{1.3}$ alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl group; a naphthyl group; a quinolinyl group; an indazolyl group; or a benzpyrazolyl group; an isoquinolinyl group; and

 R_b is phenyl, pyridyl or piperidyl, all of which may be substituted with one or more substituents selected from a group consisting of halide, hydroxy, cyano, lower alkyl, and lower alkoxy groups.

Application No. 10/826,972

Amendments to the Drawings:

The attached sheet of drawings includes changes to Figure 17. This sheet, Figure 17, replaces the original sheet including Figure 17.

Attachment: Replacement Sheet, Figure 17.